Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Med Oncol ; 36(2): 16, 2019 Jan 08.
Artículo en Inglés | MEDLINE | ID: mdl-30617767

RESUMEN

Splenectomy before allogeneic stem cell transplantation (ASCT) for patients with myelofibrosis (MF) remains a matter of debate, and conflicting results have been reported to date. The procedure seems to fasten post-transplant hematological recovery, but it does not have an impact on survival. The role of pre-transplant splenic irradiation (SI) is much more difficult to evaluate. Forty-four patients (25 males and 19 females) with MF at median age of 49 years at diagnosis (range 14-67) underwent ASCT. The post-transplant outcome was compared between irradiated and non-irradiated patients. Eleven patients received irradiation before transplantation. Median dose of radiation was 1000 cGy (range 600-2400). There was no difference in median time to engraftment between patients with and without previous radiotherapy. Acute and chronic graft versus host disease (GVHD) occurred in 47% and 36% of patients, respectively. There was no difference in GVHD incidence between groups. Eight patients relapsed/progressed in irradiated group versus 17 in non-irradiated (70% vs. 51%; p = 0.3). Transformation to acute myeloid leukemia was observed in 3 patients: 2 in irradiated and 1 in non-irradiated group. In total, 22 patients died with no statistical difference in death rate between irradiated and non-irradiated subjects. The probability of overall survival after transplant for the entire cohort at 2 years was 54% (72% for irradiated and 48% for non-irradiated patients; p = 0.25). Splenic irradiation prior to ASCT for myelofibrosis has not beneficial effect on post-transplant outcome.


Asunto(s)
Mielofibrosis Primaria/terapia , Bazo/efectos de la radiación , Trasplante de Células Madre/métodos , Adolescente , Adulto , Anciano , Estudios de Cohortes , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mielofibrosis Primaria/radioterapia , Tasa de Supervivencia , Trasplante Homólogo , Resultado del Tratamiento , Adulto Joven
2.
Virchows Arch ; 445(1): 83-9, 2004 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15278450

RESUMEN

Crystal-storing histiocytosis (CSH) with massive accumulation of particulate immunoglobulins is a rare phenomenon accompanying B-cell dyscrasias. In the reported case (M51), the disease presented as systemic CSH and later was proved to be a frank multiple myeloma. The aggregates of crystal-laden histiocytes were demonstrated in the bone marrow, lungs, kidney, and liver. Additionally, the crystalline immunoglobulin particles were identified in renal stromal cells and in hepatocytes. The patient developed lung adenocarcinoma and died 12 months after the presentation, shortly after the lobectomy. In this paper, we report the results of morphological (including electron microscopy), immunohistochemical, and biochemical analysis. The tendency for aggregation of the IgG kappa monoclonal protein was due to the abnormal physicochemical properties of its heavy chain. Massive accumulation of crystal-storing histiocytes surpassed the myeloma tumor burden and markedly contributed to the severity of the disease.


Asunto(s)
Histiocitosis de Células de Langerhans , Cadenas Pesadas de Inmunoglobulina/inmunología , Mieloma Múltiple/patología , Médula Ósea/metabolismo , Médula Ósea/patología , Cristalización , Diagnóstico Diferencial , Resultado Fatal , Histiocitos/inmunología , Histiocitos/metabolismo , Histiocitos/patología , Histiocitosis de Células de Langerhans/inmunología , Histiocitosis de Células de Langerhans/metabolismo , Histiocitosis de Células de Langerhans/patología , Humanos , Cadenas Pesadas de Inmunoglobulina/metabolismo , Masculino , Persona de Mediana Edad , Mieloma Múltiple/inmunología , Mieloma Múltiple/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA